Skip to main content

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More >>


Texas Medical Center

Phone: 832-824-4635
Fax: 832-825-1206


1102 Bates Ave., Ste. 750
Houston, TX 77030

Research Laboratory

Michele S. Redell, MD, PhD

Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine


School Education Degree Year
Baylor College of Medicine Fellowship Pediatric Hematology/Oncology 2004
Baylor College of Medicine Residency Pediatrics 2001
University of Washington Medical School Doctor of Medicine 1998
University of Washington Postgraduate Education Doctor of Philosophy 1996


Dr. Michele Redell is a member of the Leukemia Team at Texas Children’s Cancer and Hematology Center. She sees patients with leukemia in the clinic one day a week, and she supervises residents and fellows in the outpatient setting, as well.

Dr. Redell is the local Principal Investigator for the Children’s Oncology Group clinical trial for patients who are newly diagnosed with acute myeloid leukemia (AAML1031). Dr. Redell serves a number of roles within the Children’s Oncology Group AML committee, including membership on the Steering Committee and Vice Chair of Biology. She is member of the study committees for two COG clinical trials, including the upcoming therapeutic trial for children with Down Syndrome and AML (AAML1531), and the new registry and biology protocol known as Project:EveryChild (APEC14B1).

Board Certifications
American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology


Organization Name Role
American Academy of Pediatrics (AAP) Member
American Society of Hematology (ASH) Member
American Society of Pediatric Hematology-Oncology (ASPHO) Member

Research Statement

Dr. Michele Redell is a member of the leukemia team and lymphoma team. Dr. Michele Redell is also conducting research under the mentorship of Dr. David Tweardy, Chief of the Section of Infectious Diseases at Baylor College of Medicine. She is interested in understanding the molecular steps that determine whether an immature cell in the bone marrow becomes a normal mature neutrophil or a malignant leukemia cell. Dr. Michele Redell is focusing on a signaling protein known as Stat3, which has two main variants and is activated in response to cytokines that control myeloid cell survival, proliferation, and maturation. She is investigating the distinct roles of the Stat3 variants in normal neutrophil development in mice. Stat3 is also known to be an important protein in many kinds of cancer, including acute myeloid leukemia (AML). Dr. Michele Redell is studying the mechanisms by which Stat3 becomes inappropriately activated in AML. With Dr. Tweardy, she is working with new agents that can block Stat3, to test their potential effectiveness as novel therapies for cancers including AML.



* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.